# IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

> **NCT07716826** · — · NOT_YET_RECRUITING · sponsor: **French Cardiology Society** · enrollment: 150 (estimated)

## Conditions studied

- Cardiomyopathy, Hypertrophic Obstructive

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07716826
- **Lead sponsor:** French Cardiology Society
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716826, "IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07716826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*